Back to Research Home
VCELVericel Corp Ord
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · Mid
$42.53−1.02%
As of 23 Oct 2026Mkt cap $2.1B
Stage 13
AVOID
Fundamentals
36.7/75
Technical
8.4/15
Independent
45.1/90
GCAE viewFundamental /75 is below the Stage 13 acceptable-business floor
Price
- 1M
- +8.2%
- 3M
- −6.2%
- 6M
- +19.3%
- 1Y
- +16.7%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 101.3xHist median 381.7x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 36.0x
- FCF yield
- 2.8%
Quality
- ROIC
- 3.1%
- Operating margin
- 1.9%
- FCF margin
- 9.0%
- Current ratio
- 5.0x
Growth
- Revenue growth
- +16.5%Latest FY YoY
- Revenue CAGR
- +15.3%
- EPS CAGR
- —
- FCF CAGR
- +4.0%
Capital
- Share-count trend
- +4.7%3Y annualised
- Net cash
- $4M-0.1x OCF
Annual trend
- CAGR 2021–2025
- +15.3%
- Latest · 2025
- $0B
- YoY
- +16.5%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- EARLY IGNITION
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- UNRESEARCHED · NEW RESEARCH
Key takeaway
Awaiting four-lens research.
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-05
- New current Route A/Route B candidate has no completed four-lens research.
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- approaching-support
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded